(2016) Efficacy and safety of Lactobacillus reuteri DSMZ17648 in Helicobacter pylori infection with no indications for absolute eradication therapy. THERAPIST. 5, www.lvrach.ru [10]Uspienskiy et al (2016). Evolution in eradication therapy of HP – associated diseases: beyond the standards?
Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans. Nutrients 5.3062-3073 三、含有罗伊氏乳杆DSM17648的益生菌选择 罗伊氏乳杆DSM17648安全性保障,通过欧洲QPS、美国GRAS等多国认证,目前在全球多个品牌都有应用。 之前看到过一个篇关于罗伊...
6.publicationUspensky etal., 2016publication 在三项独立发表的人体研究中， Pylopass™补充剂持续显著降 低幽门螺杆菌数量 1.Study 1: Mehling H & Busjahn A (2013) Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to H. pylori control. Nutrients 5: 3062-3072 2.Holz ...